HOOKIPA Pharma to Present at SVB Leerink’s CybeRx Series Vaccine Forum
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announces participation in the SVB Leerink’s CybeRx Series: Vaccine Forum on September 23-24, 2020. A fireside chat featuring CEO Joern Aldag and CMO Igor Matushansky will occur on September 23 at 12:00 PM ET. HOOKIPA focuses on developing immunotherapeutics for infectious diseases and cancers using their proprietary arenavirus platform. Their technologies include non-replicating and replicating platforms, with a Phase 2 trial ongoing for a Cytomegalovirus vaccine. They also collaborate with Gilead Sciences for HIV and Hepatitis B research.
- None.
- None.
NEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at SVB Leerink’s CybeRx Series: Vaccine Forum, taking place September 23 – 24, 2020:
- HOOKIPA Fireside Chat: Wednesday, September 23rd at 12:00 PM ET with Joern Aldag (CEO) and Igor Matushansky (CMO)
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that reprograms the body’s immune system.
HOOKIPA’s proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s “off-the-shelf” viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.
HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.
In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND application was cleared by the FDA in June 2020.
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
| Media | Investors |
| Nina Waibel | Matt Beck |
| Senior Director - Communications | Executive Director - Investor Relations |
| nina.waibel@hookipapharma.com | matthew.beck@hookipapharma.com |
FAQ
What is HOOKIPA Pharma's participation in the CybeRx Series: Vaccine Forum?
When is HOOKIPA's fireside chat scheduled?
What is the focus of HOOKIPA Pharma's research?
What clinical trials are currently underway for HOOKIPA's products?
What collaborations has HOOKIPA Pharma established recently?
